Literature DB >> 27235129

A significant correlation between delayed cure after microvascular decompression and positive response to preoperative anticonvulsant therapy in patients with hemifacial spasm.

Shunsuke Terasaka1, Katsuyuki Asaoka2, Shigeru Yamaguchi3, Hiroyuki Kobayashi3, Hiroaki Motegi3, Kiyohiro Houkin3.   

Abstract

Although microvascular decompression (MVD) is a reliable treatment for hemifacial spasm (HFS), the postoperative course is varied. We retrospectively analyzed the resolution pattern of the spasm and specified predictors for delayed cure after MVD. This study included 114 consecutive patients with typical HFS. All of them were followed up for at least 1 year after operation. Patients were divided into three groups depending on the postoperative course: immediate cure, delayed cure, and failure. To identify the predictive factors for delayed cure after MVD, logistic regression analyses were applied using candidate clinical factors, such as duration of symptom, the tendency of the spasm, preoperative medical treatment, and offending vessels. Among the 114 patients, 107 patients were cured. For those cured, 65 patients were classified as immediate cure and 42 patients were classified as delayed cure. Cumulative spasm-free rates after 1 week, 1 month, and 3 months after MVD were 70, 88, and 97 %, respectively. No predictive factors between the cured and failure groups were observed. According to multivariate analysis, preoperative anticonvulsant therapy was found to be the sole significant predictive factor for delayed cure after MVD (p = 0.025). A significant correlation between delayed cure and preoperative anticonvulsant therapy was found in our study, which suggests that hyperexcitation of the facial nucleus plays an important role in pathogenesis of delayed cure. Therefore, if a patient demonstrating a positive response to preoperative anticonvulsant therapy showed a persistent spasm after MVD, reoperation should be delayed for at least 3 months after the initial operation.

Entities:  

Keywords:  Anticonvulsant therapy; Clonazepam; Delayed cure; Hemifacial spasm; Microvascular decompression

Mesh:

Substances:

Year:  2016        PMID: 27235129     DOI: 10.1007/s10143-016-0729-4

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  23 in total

Review 1.  Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm: a systematic review.

Authors:  Larry E Miller; Valerie M Miller
Journal:  Br J Neurosurg       Date:  2011-12-15       Impact factor: 1.596

2.  Reoperation for persistent or recurrent hemifacial spasm after microvascular decompression.

Authors:  Yong S Park; Jong H Chang; Joon Cho; Yong G Park; Sang S Chung; Jin W Chang
Journal:  Neurosurgery       Date:  2006-06       Impact factor: 4.654

3.  Microvascular decompression for hemifacial spasm: focus on late reoperation.

Authors:  Xuhui Wang; Parthasarathy D Thirumala; Aalap Shah; Paul Gardner; Miguel Habeych; Donald Crammond; Jeffrey Balzer; Lois Burkhart; Michael Horowitz
Journal:  Neurosurg Rev       Date:  2013-06-10       Impact factor: 3.042

4.  Intraoperative monitoring of facial EMG responses during microvascular decompression for hemifacial spasm. Prognostic value for long-term outcome: a study in a 33-patient series.

Authors:  J Hatem; M Sindou; C Vial
Journal:  Br J Neurosurg       Date:  2001-12       Impact factor: 1.596

5.  Prospective study of microvascular decompression in hemifacial spasm.

Authors:  J C Shin; U H Chung; Y C Kim; C I Park
Journal:  Neurosurgery       Date:  1997-04       Impact factor: 4.654

6.  Abnormal muscle response monitoring during microvascular decompression for hemifacial spasm.

Authors:  S Yamashita; T Kawaguchi; M Fukuda; M Watanabe; R Tanaka; S Kameyama
Journal:  Acta Neurochir (Wien)       Date:  2005-07-11       Impact factor: 2.216

7.  Delayed resolution of residual hemifacial spasm after microvascular decompression operations.

Authors:  M Ishikawa; T Nakanishi; Y Takamiya; J Namiki
Journal:  Neurosurgery       Date:  2001-10       Impact factor: 4.654

Review 8.  [Neurosurgical treatment of primary hemifacial spasm with microvascular decompression].

Authors:  M Sindou; Y Keravel
Journal:  Neurochirurgie       Date:  2009-03-28       Impact factor: 1.553

9.  Microvascular decompression for hemifacial spasm.

Authors:  F G Barker; P J Jannetta; D J Bissonette; P T Shields; M V Larkins; H D Jho
Journal:  J Neurosurg       Date:  1995-02       Impact factor: 5.115

10.  Relation between the persistence of an abnormal muscle response and the long-term clinical course after microvascular decompression for hemifacial spasm.

Authors:  Hana Tobishima; Toru Hatayama; Hiroki Ohkuma
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-12-05       Impact factor: 1.742

View more
  4 in total

1.  Spasm Freedom Following Microvascular Decompression for Hemifacial Spasm: Systematic Review and Meta-Analysis.

Authors:  Katherine Holste; Ronald Sahyouni; Zoe Teton; Alvin Y Chan; Dario J Englot; John D Rolston
Journal:  World Neurosurg       Date:  2020-04-16       Impact factor: 2.104

2.  Factors Related to the Delayed Cure of Hemifacial Spasm after Microvascular Decompression: An Analysis of 175 Consecutive Patients.

Authors:  Yosuke Sato; Katsuyoshi Shimizu; Kazuki Iizuka; Ryo Irie; Masaki Matsumoto; Tohru Mizutani
Journal:  J Neurol Surg B Skull Base       Date:  2021-12-29

3.  Endoscopic assisted microvascular decompression for vertebral artery - Associated hemifacial spasm - A case report.

Authors:  Anh Hoang Pham; Ha Dai Duong; Hung Thanh Chu; Hai Trung Vu; Dung Tuan Pham; He Van Dong
Journal:  Ann Med Surg (Lond)       Date:  2022-03-03

4.  The Underlying Pathogenesis of Neurovascular Compression Syndromes: A Systematic Review.

Authors:  Bartosz Szmyd; Julia Sołek; Maciej Błaszczyk; Jakub Jankowski; Paweł P Liberski; Dariusz J Jaskólski; Grzegorz Wysiadecki; Filip F Karuga; Agata Gabryelska; Marcin Sochal; R Shane Tubbs; Maciej Radek
Journal:  Front Mol Neurosci       Date:  2022-07-04       Impact factor: 6.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.